{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:04:42Z","timestamp":1786539882803,"version":"build-2736575974"},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate current patterns and outcomes of intravesical bacillus Calmette\u2013Gu\u00e9rin treatment in Japanese patients with bladder cancer, including the proportion of patients completing induction therapy, and time to subsequent treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study utilized administrative claims data from the Medical Data Vision Co., Ltd. database to identify patients with a diagnosis of bladder cancer who had received \u22651 prescription of intravesical bacillus Calmette\u2013Gu\u00e9rin between April 2008 and September 2015, and had \u22651 database record dated \u226512\u2009weeks after the initial bacillus Calmette\u2013Gu\u00e9rin dose. Patients were followed until September 2018, the last date of available data, or in\u2010hospital death. Patients receiving six doses of bacillus Calmette\u2013Gu\u00e9rin at intervals of &lt;21\u2009days were considered to have completed induction according to guidelines. Time from initial bacillus Calmette\u2013Gu\u00e9rin dose to subsequent bladder cancer treatment after the end of treatment was defined as the recurrence\u2010free duration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 6140 patients identified (median age 73.0\u2009years; 83.4% males), 4588 (74.7%) completed induction and 1552 (25.3%) did not. Median recurrence\u2010free duration was 64.4, 77.7, and 31.6\u2009months in the overall, complete\u2010induction and incomplete\u2010induction cohorts, respectively. Corresponding 3\u2010year recurrence\u2010free rate was 56.3%, 59.0%, and 48.2% in these groups. The rate of cystectomy was approximately 6% at 5\u2009years in all cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Approximately 75% of Japanese patients who undergo intravesical bacillus Calmette\u2013Gu\u00e9rin treatment receive a guideline\u2010compliant induction regimen, but outcomes were not satisfactory, highlighting the need for more effective treatments for non\u2010muscle invasive bladder cancer.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.14933","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T06:24:34Z","timestamp":1653200674000},"page":"1120-1129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real\u2010world treatment patterns and clinical outcomes of Japanese patients with non\u2010muscle invasive bladder cancer receiving intravesical bacillus Calmette\u2013Gu\u00e9rin treatment"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"first","affiliation":[{"name":"Department of Urology Nara Medical University  Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-6676","authenticated-orcid":false,"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Urology St. Marianna University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Piao","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuya","family":"Hayashi","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Koto","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Jinushi","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-2816","authenticated-orcid":false,"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology Kyoto University Graduate School of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"International Agency for Research on Cancer.Bladder cancer fact sheet. Source: Globocan. 2020. [Cited 28 Apr 2021.] Available from URL:https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/30\u2010Bladder\u2010fact\u2010sheet.pdf"},{"key":"e_1_2_13_3_1","unstructured":"International Agency for Research on Cancer.Estimated number of new cases from 2020 to 2040 both sexes age [0\u201385+]: bladder. [Cited 30 Dec 2020.] Available from URL:https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/isotype?cancers=30&single_unit=50000"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.010"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.04.051"},{"key":"e_1_2_13_6_1","unstructured":"ChangSS BoorjianSA ChouRet\u00a0al. Diagnosis and treatment of non\u2010muscle invasive bladder cancer: AUA\/SUO guideline 2016 amended. 2020. [Cited 28 Apr 2021.] Available from URL:https:\/\/www.auanet.org\/guidelines\/bladder\u2010cancer\u2010non\u2010muscle\u2010invasive\u2010guideline"},{"key":"e_1_2_13_7_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology: bladder cancer. Version 6.2020. [Cited 28 Apr 2021.] Available from URL:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14281"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.12.090"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11194.x"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.58"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2008.02235.x"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.11.033"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61607-0"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.02.040"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-14-11"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.16"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-159002"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.028"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.14933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.14933","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.14933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T04:03:29Z","timestamp":1692677009000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.14933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/iju.14933"],"URL":"https:\/\/doi.org\/10.1111\/iju.14933","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"2021-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}